Elanco Animal Health (NYSE:ELAN) Given New $30.00 Price Target at JPMorgan Chase & Co.

Elanco Animal Health (NYSE:ELAN) had its price target increased by stock analysts at JPMorgan Chase & Co. from $28.00 to $30.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 25.03% from the stock’s previous close.

ELAN has been the topic of several other reports. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday, April 27th. Wall Street Zen downgraded Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 18th. Citigroup started coverage on Elanco Animal Health in a report on Wednesday, April 15th. They issued a “buy” rating and a $30.00 price target on the stock. UBS Group reiterated a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Finally, Leerink Partners increased their price target on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.10.

Elanco Animal Health Trading Down 8.3%

ELAN stock traded down $2.19 during midday trading on Thursday, reaching $24.00. 8,155,888 shares of the company traded hands, compared to its average volume of 5,021,183. Elanco Animal Health has a 52-week low of $11.83 and a 52-week high of $27.72. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17. The business has a 50 day moving average of $23.85 and a 200-day moving average of $23.33. The firm has a market capitalization of $11.93 billion, a price-to-earnings ratio of -50.20, a P/E/G ratio of 2.93 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.34 by $0.06. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The firm’s revenue was up 14.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, sell-side analysts expect that Elanco Animal Health will post 1.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. NewEdge Advisors LLC grew its holdings in Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after acquiring an additional 627 shares in the last quarter. Root Financial Partners LLC grew its holdings in Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after acquiring an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. bought a new position in Elanco Animal Health during the 4th quarter worth about $41,000. Huntington National Bank boosted its position in Elanco Animal Health by 136.7% during the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after acquiring an additional 1,087 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. boosted its position in Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after acquiring an additional 900 shares in the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Key Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Quarterly beat — Elanco reported Q1 adjusted EPS of $0.40 (vs. $0.34 consensus) and revenue of $1.371B (+15% YoY; 10% organic), with adjusted EBITDA of $334M and improving margins. These results validate the company’s innovation-led growth. Elanco Animal Health Reports First Quarter 2026 Results
• Positive Sentiment: Upgraded full-year targets — Elanco raised FY2026 guidance (revenue to $5.010B–$5.085B, adjusted EBITDA to $975M–$1,005M, adjusted EPS to $1.03–$1.09) and raised its innovation revenue target to $1.2B; management also tightened year-end net leverage goals to ~3.0–3.2x. These lifts are supportive of forward earnings growth. Elanco Animal Health Reports First Quarter 2026 Results
• Positive Sentiment: Regulatory/product momentum — The company announced emergency use authorizations for Negasunt Powder and Tanidil, supporting near-term product revenue and pipeline proof points that investors value. Elanco Animal Health Moves Higher On Earnings Strength And Product Momentum
• Neutral Sentiment: Earnings materials available — Full earnings call transcript and the investor presentation/slide deck were released (useful for details on segments, geography and margin drivers). Elanco Q1 2026 Earnings Call Transcript Q1 Results – Earnings Call Presentation
• Negative Sentiment: Q2 guide slightly soft vs. consensus — Elanco guided Q2 EPS to $0.250–$0.285 vs. a consensus near $0.29 (revenues roughly in line). That miss on the midpoint may have trimmed near-term expectations and contributed to profit-taking after the rally. Elanco Animal Health Reports First Quarter 2026 Results

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.